Novartis to buy 25% of Alcon

Novartis is to purchase 25% of Alcon from majority stakeholder Nestlé, with an option to purchase Nestlé's remaining shares, which currently amount to approximately 52% of Alcon.

Related Content:

ArticlesCataract & Refractive

Opportunities lie ahead at the 39th ‘hybrid’ ESCRS

Ultra-widefield imaging improves visibility of retina and optic nerve in KPro patients

Cataract surgeons on operating theatre waste: Less is often more